Published in Expert Rev Anticancer Ther on May 01, 2009
Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 67.34
A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naïve patients with advanced melanoma. Invest New Drugs (2010) 2.09
Personalized tumor response assessment in the era of molecular medicine: cancer-specific and therapy-specific response criteria to complement pitfalls of RECIST. AJR Am J Roentgenol (2012) 1.69
Current management and novel agents for malignant melanoma. J Hematol Oncol (2012) 1.53
Combining radiation and immunotherapy: a new systemic therapy for solid tumors? Cancer Immunol Res (2014) 1.43
A new understanding in the epidemiology of melanoma. Expert Rev Anticancer Ther (2010) 1.30
Immune-mediated adverse events associated with ipilimumab ctla-4 blockade therapy: the underlying mechanisms and clinical management. Scientifica (Cairo) (2013) 1.28
Ipilimumab (yervoy) prolongs survival in advanced melanoma: serious side effects and a hefty price tag may limit its use. P T (2012) 1.19
Aldehyde dehydrogenase (ALDH) activity does not select for cells with enhanced aggressive properties in malignant melanoma. PLoS One (2010) 1.15
Emerging targeted therapies for melanoma treatment (review). Int J Oncol (2014) 1.10
Characteristics and management of immunerelated adverse effects associated with ipilimumab, a new immunotherapy for metastatic melanoma. Cancer Manag Res (2012) 1.08
Targeting the RAS pathway in melanoma. Trends Mol Med (2011) 0.98
Cutaneous melanoma in situ: translational evidence from a large population-based study. Oncologist (2011) 0.96
Augmentation of therapeutic responses in melanoma by inhibition of IRAK-1,-4. Cancer Res (2012) 0.90
Translatability scoring in drug development: eight case studies. J Transl Med (2012) 0.89
Membrane transport proteins in human melanoma: associations with tumour aggressiveness and metastasis. Br J Cancer (2010) 0.89
Association of inherited variation in Toll-like receptor genes with malignant melanoma susceptibility and survival. PLoS One (2011) 0.88
Therapeutic options in cutaneous melanoma: latest developments. Ther Adv Med Oncol (2011) 0.87
Germline CDKN2A mutations in Brazilian patients of hereditary cutaneous melanoma. Fam Cancer (2014) 0.86
Ipilimumab retreatment in patients with pretreated advanced melanoma: the expanded access programme in Italy. Br J Cancer (2014) 0.84
Clinical experience with ipilimumab 10 mg/kg in patients with melanoma treated at Italian centres as part of a European expanded access programme. J Exp Clin Cancer Res (2013) 0.84
Systematic review and network meta-analysis of overall survival comparing 3 mg/kg ipilimumab with alternative therapies in the management of pretreated patients with unresectable stage III or IV melanoma. Oncologist (2012) 0.83
Identification of differentially expressed microRNAs in metastatic melanoma using next-generation sequencing technology. Int J Mol Med (2014) 0.81
Q-TWiST analysis comparing ipilimumab/dacarbazine vs placebo/dacarbazine for patients with stage III/IV melanoma. Br J Cancer (2013) 0.80
Bi-cytopenia possibly induced by anti-PD-1 antibody for primary malignant melanoma of the esophagus: A case report. Medicine (Baltimore) (2016) 0.80
Efficacy of combined axitinib with dacarbazine in a B16F1 melanoma xenograft model. Oncol Lett (2013) 0.79
Ipilimumab for advanced melanoma: a pharmacologic perspective. J Oncol Pharm Pract (2012) 0.79
Real-world impact of education: treating patients with ipilimumab in a community practice setting. Cancer Manag Res (2013) 0.78
Late onset ipilimumab-induced pericarditis and pericardial effusion: a rare but life threatening complication. Case Rep Oncol Med (2015) 0.78
Multiple metastatic malignant melanoma presenting intraluminal gallbladder bleeding. Int Surg (2014) 0.78
Emerging options for the treatment of melanoma - focus on ipilimumab. Immunotargets Ther (2014) 0.77
Phase I-II study of plitidepsin and dacarbazine as first-line therapy for advanced melanoma. Br J Cancer (2013) 0.77
Population-based estimates of survival and cost for metastatic melanoma. Curr Oncol (2015) 0.77
Ipilimumab: A First-in-Class T-Cell Potentiator for Metastatic Melanoma. J Skin Cancer (2013) 0.76
High ALDH1 expression correlates with better prognosis in tumorigenic malignant melanoma. Mod Pathol (2017) 0.75
Burden of illness for metastatic melanoma in Canada, 2011-2013. Curr Oncol (2016) 0.75
Metastatic Melanoma: Treatment and Survival in the US after the Introduction of Ipilimumab and Vemurafenib. Oncol Res Treat (2017) 0.75
A new frontier in treatment of advanced melanoma: Redefining clinical management in the era of immune checkpoint inhibitors. Hum Vaccin Immunother (2017) 0.75
The use of the EVITA algorithm for clinical assessment of novel agents used in prostate cancer, metastatic melanoma, and systemic lupus erythematosus. Eur J Clin Pharmacol (2014) 0.75
A natural product-like JAK2/STAT3 inhibitor induces apoptosis of malignant melanoma cells. PLoS One (2017) 0.75
Resource utilization and costs of managing patients with advanced melanoma: a Canadian population-based study. Curr Oncol (2017) 0.75